396 related articles for article (PubMed ID: 35493518)
21. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
22. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
23. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
[TBL] [Abstract][Full Text] [Related]
24. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
[TBL] [Abstract][Full Text] [Related]
25. Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.
Ding R; Zhao C; Jing Y; Chen R; Meng Q
BMC Med Genomics; 2023 Apr; 16(1):81. PubMed ID: 37081465
[TBL] [Abstract][Full Text] [Related]
26. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
27. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
28. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.
Liang L; Li C; Wang MD; Wang H; Zhou YH; Zeng YY; Zhang WG; Chen TH; Wang NY; Li J; Zhang YM; Wang Y; Gu WM; Xing H; Diao YK; Lau WY; Zhang CW; Pawlik TM; Shen F; Huang DS; Yang T
J Hematol Oncol; 2021 Oct; 14(1):165. PubMed ID: 34641921
[TBL] [Abstract][Full Text] [Related]
30. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
31. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
32. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
33. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q; Xia D; Bai W; Wang E; Sun J; Huang M; Mu W; Yin G; Li H; Zhao H; Li J; Zhang C; Zhu X; Wu J; Li J; Gong W; Li Z; Lin Z; Pan X; Shi H; Shao G; Liu J; Yang S; Zheng Y; Xu J; Song J; Wang W; Wang Z; Zhang Y; Ding R; Zhang H; Yu H; Zheng L; Gu W; You N; Wang G; Zhang S; Feng L; Liu L; Zhang P; Li X; Chen J; Xu T; Zhou W; Zeng H; Zhang Y; Huang W; Jiang W; Zhang W; Shao W; Li L; Niu J; Yuan J; Li X; Lv Y; Li K; Yin Z; Xia J; Fan D; Han G;
J Hepatol; 2019 May; 70(5):893-903. PubMed ID: 30660709
[TBL] [Abstract][Full Text] [Related]
34. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
Front Immunol; 2022; 13():843408. PubMed ID: 35693827
[TBL] [Abstract][Full Text] [Related]
36. Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment.
Zhu L; Zhang XP; Xu S; Hu MG; Zhao ZM; Zhao GD; Xiao ZH; Liu R
Front Immunol; 2022; 13():1111246. PubMed ID: 36700197
[TBL] [Abstract][Full Text] [Related]
37. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
Yang Z; Zi Q; Xu K; Wang C; Chi Q
Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
[TBL] [Abstract][Full Text] [Related]
38. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Oncology; 2014; 87 Suppl 1():32-6. PubMed ID: 25427731
[TBL] [Abstract][Full Text] [Related]
39. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
40. [Expert consensus on transarterial chemoembolization refractoriness and subsequent therapies in hepatocellular carcinoma].
Clinical Guidelines Committee of Chinese College of Interventionalists
Zhonghua Nei Ke Za Zhi; 2022 Aug; 61(8):860-866. PubMed ID: 35922209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
